After three randomized trials inclusive of only 247 women, and with side effects that include loss of consciousness, brexanolone has been approved for the treatment of postpartum depression. Because of the drug’s risk profile, women must receive the 60-hour infusion under medical supervision and “cannot function as her child(ren)’s primary caregiver.”
The issue of how women in crisis are supported after a birth is personally relevant. One day I hope to have a child. As someone whose distress sometimes takes the form of psychosis, I was eager to connect with the stories of women who had trodden this path before me.